Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) insider Thomas K. Equels purchased 29,404 shares of the stock in a transaction on Friday, June 21st. The shares were bought at an average cost of $4.03 per share, for a total transaction of $118,498.12. Following the transaction, the insider now directly owns 1,393,611 shares in the company, valued at $5,616,252.33. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of NYSEAMERICAN HEB opened at $4.16 on Monday. Hemispherx BioPharma, Inc has a 12 month low of $3.62 and a 12 month high of $14.81.

Hemispherx BioPharma (NYSEAMERICAN:HEB) last issued its earnings results on Thursday, May 16th. The specialty pharmaceutical company reported ($3.08) EPS for the quarter.

HEB has been the topic of several recent analyst reports. Maxim Group initiated coverage on Hemispherx BioPharma in a research report on Friday, June 14th. They set a “buy” rating and a $8.00 price target on the stock. Ascendiant Capital Markets set a $44.00 price target on Hemispherx BioPharma and gave the stock a “buy” rating in a research report on Friday, May 17th.

Hemispherx BioPharma Company Profile

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Featured Article: What is the balance sheet?

Insider Buying and Selling by Quarter for Hemispherx BioPharma (NYSEAMERICAN:HEB)

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.